| Data Sharing Statement |   |  |
|------------------------|---|--|
| Article<br>Info        | https://dx.doi.org/10.21037/jgo-22-1237   |  |
| Item                   | Question  | Authors' Response<br>(place "-" if not applicable)   |
| 1                      | Would you like to share data collected for your study to others?  | Yes.   |
| 2                      | If not, would you like to share the reason for your decision?   | -  |
| 3                      | What data in particular will be shared?   | The survival data will be shared.  |
| 4                      | Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Statistical analysis plan will be shared if requested.   |
| 5                      | When will data availability begin?  | From the publication date.   |
| 6                      | When will data availability end?  | Two years within the publication date since the technique or survival data may be updated over time.             |
| 7                      | To whom will you share the data?  | Medical oncologists and surgeons who are interested in studies of anti-EGFR therapy.                             |
| 8                      | For what type of analysis or purpose?   | To analyze and evaluate the efficacy of anti-EGFR therapy in patients with colon cancer.                         |
| 9                      | How or where can the data/documents be obtained?  | Emails could be sent to the address below to obtain the shared data: thm5232201@163.com.                         |
| 10                     | Any other restrictions?   | We may balance the potential benefits and risks for each request and then provide the data that could be shared. |